تقرير
أعرض في EDS

Different immune contextures underlie tumor site-specific responses to immune checkpoint blockade in esophageal cancer.

التفاصيل البيبلوغرافية
العنوان: Different immune contextures underlie tumor site-specific responses to immune checkpoint blockade in esophageal cancer.
المؤلفون: Guo JC; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Hsu CL; Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan., Hsieh MS; Department of Pathology, National Taiwan University Cancer Center, Taipei, Taiwan., Lin CC; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Huang TC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan., Kuo HY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan., Shao YY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan., Hsu CH; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
المصدر: Thoracic cancer [Thorac Cancer] 2023 Aug; Vol. 14 (22), pp. 2216-2221. Date of Electronic Publication: 2023 Jun 20.
نوع المنشور: Case Reports; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley Publishing Asia Pty Ltd Country of Publication: Singapore NLM ID: 101531441 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-7714 (Electronic) Linking ISSN: 17597706 NLM ISO Abbreviation: Thorac Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: November 2012- : Singapore : Tianjin : Wiley Publishing Asia Pty Ltd ; Tianjin Lung Cancer Institute
Original Publication: Richmond, Vic. : Tianjin : Blackwell Pub. Asia Pty Ltd. ; Tianjin Lung Cancer Institute
مواضيع طبية MeSH: Esophageal Neoplasms*/pathology , Esophageal Squamous Cell Carcinoma*/pathology , Liver Neoplasms*, Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunohistochemistry
مستخلص: Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in advanced esophageal squamous cell carcinoma (ESCC). Heterogeneous responses to ICIs have been reported previously. Here, we describe a patient with advanced ESCC exhibiting a response to durvalumab plus tremelimumab for more than 6 months except primary resistant esophageal tumor. The esophageal tumor had higher regulatory T cells, neutrophils, and mast cells scores estimated by NanoString platform than hepatic tumor. The immunohistochemistry study confirmed higher expression levels of Foxp3, and myeloperoxidase (MPO) in the esophageal tumor. The different immune contextures may underlie the heterogeneous responses to ICI combination in this ESCC patient.
(© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
References: Br J Cancer. 2016 Nov 8;115(10):1186-1192. (PMID: 27701388)
J Formos Med Assoc. 2020 Feb;119(2):565-568. (PMID: 31668650)
J Clin Oncol. 2020 Dec 10;38(35):4138-4148. (PMID: 33026938)
NPJ Genom Med. 2017;2:. (PMID: 28819565)
J Thorac Oncol. 2015 Oct;10(10):1481-9. (PMID: 26313683)
Cancer Med. 2022 Jul;11(13):2550-2560. (PMID: 35611499)
J Clin Invest. 2017 Aug 1;127(8):2930-2940. (PMID: 28650338)
Oncology. 2021;99(10):652-658. (PMID: 34340231)
Lancet Oncol. 2017 Mar;18(3):312-322. (PMID: 28131785)
Anticancer Res. 2019 Oct;39(10):5675-5682. (PMID: 31570466)
J Immunother Cancer. 2017 Feb 21;5:18. (PMID: 28239471)
Thorac Cancer. 2023 Aug;14(22):2216-2221. (PMID: 37340770)
Nat Commun. 2022 Feb 14;13(1):857. (PMID: 35165274)
J Formos Med Assoc. 2023 Jan;122(1):4-8. (PMID: 35680471)
Nat Med. 2018 Jun;24(6):749-757. (PMID: 29867230)
فهرسة مساهمة: Keywords: differential response; esophageal squamous cell carcinoma; immune checkpoint inhibitor; immune contexture; tumor site specific
المشرفين على المادة: 0 (Immune Checkpoint Inhibitors)
تواريخ الأحداث: Date Created: 20230621 Date Completed: 20230804 Latest Revision: 20230805
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10396778
DOI: 10.1111/1759-7714.14997
PMID: 37340770
قاعدة البيانات: MEDLINE
الوصف
تدمد:1759-7714
DOI:10.1111/1759-7714.14997